AndroGel for Secondary Hypogonadism: Evidence, Dosing, and Clinical Guidance

What makes hypogonadism secondary?

Secondary hypogonadism is a signaling problem, not a testicular one. The testosterone gel 1% label defines hypogonadotropic hypogonadism as gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma or radiation; testosterone is low while LH and FSH sit in the normal or low range [1]. In primary hypogonadism the testes fail, and LH and FSH usually run above the normal range [1].

That difference has practical consequences. Clomiphene can raise LH and FSH and is described as preserving intratesticular testosterone and spermatogenesis, whereas exogenous androgens may lead to azoospermia [4][1]. Once deficiency is confirmed, the Endocrine Society guideline recommends further testing — LH and FSH among other tests — to separate primary from secondary causes [2]. Symptomatic hypogonadism can also follow anabolic steroid use [5].

Is the gel FDA-labeled for secondary hypogonadism?

Yes. The testosterone gel 1% label covers replacement therapy in adult men with primary hypogonadism or hypogonadotropic hypogonadism [1]. FDA states that approved testosterone products are for men who lack testosterone or have low testosterone together with an associated medical condition, such as testicular failure or a hypothalamic or pituitary problem, and that no approved product is for men with low testosterone who lack such a condition [6].

AndroGel is approved as a 1% gel and a 1.62% gel, and the two have different dosing instructions [1]. The dosing, application, warning and adverse-event details below come from the testosterone gel 1% label [1]. TRAVERSE used AndroGel 1.62% [6].

Two labeling points are worth knowing. The label carries a Limitation of Use saying safety and efficacy in age-related (late-onset) hypogonadism have not been established [1]. FDA asked manufacturers in June 2026 to remove that limitation and to revise prostate cancer and benign prostatic hyperplasia safety information; the testosterone gel 1% label (effective September 30, 2025) still contains the limitation [6][1]. Separately, FDA's February 28, 2025 class-wide action removed language about increased cardiovascular risk from the Boxed Warning of all testosterone products and added a blood pressure warning where a product lacked one [7]. For testosterone gel 1%, the boxed warning that remains is for secondary exposure, not for heart attack or stroke [1][7].

Confirming the diagnosis before the first dose

The Endocrine Society recommends diagnosing hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone [2]. It recommends a fasting morning total testosterone measured with an accurate and reliable assay as the initial test, repeating that measurement to confirm the diagnosis, and — once deficiency is confirmed — further testing such as LH and FSH to separate primary from secondary causes [2]. The testosterone gel 1% label says to confirm the diagnosis by ensuring that morning serum testosterone has been measured on at least two separate days and that both concentrations are below the normal range [1].

The AUA guideline uses a total testosterone below 300 ng/dL as a reasonable cutoff and also requires two early-morning measurements on separate occasions; a single low value, or symptoms alone, are not enough [8]. Harmonized reference data put the lower limit of the healthy young male range at 264 ng/dL, with a median of 531 ng/dL, in 9,054 men across four cohorts [9]. The cut points differ because assays and guidelines differ [9].

Dosing testosterone gel 1%

Testosterone gel 1% has a labeled starting dose of 50 mg once daily, with adjustments to 75 or 100 mg [1]. The 1.62% gel has its own separate dosing instructions [1].

The label describes 50 mg as 4 pump actuations, two 25 mg packets or one 50 mg packet, applied once daily in the morning [1]. It directs application to clean, dry, intact skin of the shoulders and upper arms and/or abdomen, and says not to apply the gel to the genitals, chest, armpits, knees or back [1]. It also directs washing hands with soap and water immediately after application, covering the site with clothing once the gel has dried, and washing the site thoroughly before any anticipated skin-to-skin contact [1]. The gel is flammable until dry [1].

The label says the dose can be adjusted to 50, 75 or 100 mg of testosterone daily on the basis of total serum testosterone concentration, corresponding to 4, 6 or 8 pump actuations [1]. It lists serum testosterone, PSA, hemoglobin, hematocrit, liver function tests and lipids among the values to monitor periodically [1]. The 1% gel label also notes that topical testosterone products may have different doses, strengths or application instructions that produce different systemic exposure, and that its dosing differs from testosterone gel 1.62% [1].

How fast do testosterone levels rise?

In a pharmacokinetic study of 227 hypogonadal men that compared 1% gel (50 and 100 mg) with a patch, serum testosterone rose into the normal adult male range on day 1 with the first gel application. The authors cite an earlier study in which steady state was reached 48 to 72 hours after the first application, and the gel 1% label says serum concentrations are at steady state by the second or third day of dosing [1]. Pharmacokinetic parameters were very similar on days 30, 90 and 180 of daily use, and about 9 to 14% of the applied testosterone was bioavailable [10].

Symptom timing comes from a review of testosterone time-courses rather than from the gel itself: effects on sexual interest appear after about 3 weeks and plateau by 6 weeks, changes in erections and ejaculations may take up to 6 months, effects on depressed mood become detectable after 3 to 6 weeks, and fat mass and lean mass change within 12 to 16 weeks [11].

What the trials show

TRAVERSE was a multicenter randomized cardiovascular outcome trial of daily transdermal 1.62% testosterone gel in 5,246 men aged 45 to 80 with symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and existing or high risk of cardiovascular disease, randomized to testosterone gel — dose-adjusted to keep levels between 350 and 750 ng/dL — or placebo gel [3]. Mean treatment was 21.7 months and mean follow-up 33.0 months. The first major cardiovascular event occurred in 182 men (7.0%) on testosterone and 190 (7.3%) on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17), meeting noninferiority [3]. Nonfatal arrhythmias needing intervention were more frequent on testosterone (5.2% vs 3.3%), as were atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%), bone fracture (3.5% vs 2.5%) and venous thromboembolism (1.7% vs 1.2%) [3][1]. TRAVERSE used a 1.62% gel [3][6]; the 1% label reports the trial's blood pressure, cardiovascular and venous thromboembolism results in its warnings [1].

The Testosterone Trials enrolled 790 men aged 65 or older with a serum testosterone below 275 ng/dL and symptoms, treated for 1 year [12]. Testosterone increased sexual activity (P<0.001), sexual desire and erectile function, and produced slightly better mood and lower depressive symptom severity; it did not significantly improve vitality on the FACIT-Fatigue scale, and the share of men gaining at least 50 m in the 6-minute walk differed only when all three trials were pooled (20.5% vs 12.6%, P=0.003) [12]. The bone substudy of 211 men found spine trabecular volumetric bone density rose 7.5% versus 0.8% on placebo (treatment effect 6.8%, P<.001) [13]. Entry into these trials was based on age, testosterone level and symptoms, so they describe older men with low testosterone, not a group selected for a pituitary or hypothalamic cause [12].

The fertility trade-off

The label states that exogenous androgens may lead to azoospermia [1]. The Endocrine Society guideline recommends against starting testosterone therapy in men planning fertility in the near term [2], and the AUA position is that exogenous testosterone should not be prescribed to men currently trying to conceive [8].

Recovery is possible but variable. In an integrated analysis of 30 studies of 1,549 healthy eugonadal men on hormonal contraception, the median time for sperm concentration to return to 20 million/mL was 3.4 months, with 67% recovered by 6 months, 90% by 12 and 100% by 24; recovery was faster with shorter-acting testosterone and shorter treatment [14]. In 66 men with infertility after testosterone use, stopping testosterone and starting high-dose hCG plus a selective estrogen receptor modulator brought 70% to a total motile count above 5 million within 12 months, and older age and longer testosterone use predicted slower recovery [15]. A retrospective series of 49 men with azoospermia or severe oligospermia on testosterone found spermatogenesis returned or improved in 47 (95.9%) on hCG 3,000 units subcutaneously every other day plus clomiphene, tamoxifen, anastrozole or recombinant FSH, at an average of 4.6 months [16].

Options that act through the pituitary

Clomiphene citrate is a selective estrogen receptor modulator that acts centrally to raise LH and FSH. Unlike testosterone replacement, it does not suppress the hypothalamic-pituitary-gonadal axis, so intratesticular testosterone and spermatogenesis are preserved [4]. It is FDA-approved only for ovulatory dysfunction in women; use in men with low testosterone is off-label [17].

Enclomiphene was compared with 1% topical testosterone gel in a randomized phase II trial in men with secondary hypogonadism: morning testosterone, estradiol and LH rose similarly in both groups, FSH and LH increased with enclomiphene, and sperm counts were conserved [18]. Enclomiphene is not FDA-approved in any form [17]. hCG appears in the fertility-recovery literature as a way to restart sperm production after exogenous testosterone [16][15].

Side effects and monitoring

In the 180-day controlled trial of testosterone gel 1%, application-site reactions were reported by 5% of men at 50 mg, 3% at 75 mg and 4% at 100 mg; acne by 1%, 3% and 8%; and hypertension by 3%, 0% and 3% [1]. The reactions listed at 5% or more overall are acne, application site reaction, abnormal laboratory tests and prostatic disorders [1].

Hematocrit is the laboratory value the label addresses in most detail. The label directs that hematocrit be checked before treatment starts, re-evaluated 3 to 6 months after starting and then annually, and that therapy be stopped until hematocrit falls to an acceptable concentration if it becomes elevated [1]. An increase in red cell mass may increase the risk of thromboembolic events [1]. A network meta-analysis of 29 placebo-controlled trials in 3,393 men found mean hematocrit rose 3.0% on gel versus placebo (95% CI 1.8 to 4.3) [19].

Blood pressure rises modestly. In an ambulatory monitoring study, testosterone gel 1% raised mean 24-hour systolic/diastolic pressure by 1.9/1.3 mm Hg at week 16 (n=169), and by 3.0/2.2 mm Hg in men with hypertension already on treatment; the label says the product is not recommended in men with uncontrolled hypertension [1]. Venous thromboembolism has been reported with testosterone products, and the label says to evaluate for DVT or PE when symptoms suggest them [1]. PSA, prostate evaluation and lipid monitoring are also part of the label's monitoring list [1]. Testosterone is a Schedule III controlled substance [1].

The boxed warning covers secondary exposure: virilization has been reported in children who contacted unwashed or unclothed application sites, with signs including genital enlargement, pubic hair, increased erections and libido, aggressive behavior and advanced bone age. Most signs regressed once exposure stopped, but in a few cases enlarged genitalia did not fully return to age-appropriate size [1].